Analysts Set Immunocore Holdings plc (NASDAQ:IMCR) PT at $69.18

Shares of Immunocore Holdings plc (NASDAQ:IMCRGet Free Report) have been given an average rating of “Moderate Buy” by the thirteen brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $65.64.

IMCR has been the topic of a number of recent research reports. Mizuho cut shares of Immunocore from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $72.00 to $38.00 in a research note on Monday, November 11th. UBS Group began coverage on Immunocore in a research report on Thursday, October 24th. They set a “sell” rating and a $24.00 target price on the stock. Needham & Company LLC reduced their price target on Immunocore from $78.00 to $71.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Immunocore in a report on Monday, September 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Immunocore in a report on Thursday, October 24th.

Check Out Our Latest Stock Report on IMCR

Immunocore Price Performance

Shares of NASDAQ IMCR opened at $29.40 on Wednesday. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of -30.95 and a beta of 0.73. The stock has a fifty day simple moving average of $32.22 and a two-hundred day simple moving average of $34.95. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore has a 1-year low of $28.17 and a 1-year high of $76.98.

Immunocore (NASDAQ:IMCRGet Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.50. The company had revenue of $80.25 million during the quarter, compared to analyst estimates of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The firm’s revenue for the quarter was up 23.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.59) EPS. Analysts anticipate that Immunocore will post -0.94 earnings per share for the current year.

Institutional Trading of Immunocore

Institutional investors and hedge funds have recently made changes to their positions in the stock. Hennion & Walsh Asset Management Inc. raised its position in Immunocore by 6.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 22,622 shares of the company’s stock valued at $767,000 after purchasing an additional 1,390 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in Immunocore by 16.2% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 397,463 shares of the company’s stock worth $13,470,000 after buying an additional 55,463 shares during the last quarter. Fiera Capital Corp boosted its stake in Immunocore by 1.1% in the second quarter. Fiera Capital Corp now owns 875,593 shares of the company’s stock worth $29,674,000 after buying an additional 9,181 shares in the last quarter. TD Asset Management Inc grew its position in Immunocore by 23.2% during the second quarter. TD Asset Management Inc now owns 264,896 shares of the company’s stock valued at $8,977,000 after acquiring an additional 49,882 shares during the last quarter. Finally, Candriam S.C.A. raised its stake in shares of Immunocore by 65.8% during the second quarter. Candriam S.C.A. now owns 313,423 shares of the company’s stock worth $10,621,000 after acquiring an additional 124,417 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

About Immunocore

(Get Free Report

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

Featured Stories

Analyst Recommendations for Immunocore (NASDAQ:IMCR)

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.